NKTR -102

"We were encouraged to find that the CTC sub-study confirmed the presence of several potential target-specific pharmacodynamic biomarkers, such as topoisomerase 1, in the patients enrolled in our study," saidIvan Gergel, MD, senior vice president drug development and chief medical officer of Nektar Therapeutics. "The analysis from the BEACON CTC sub-study could help us better understand which additional patient populations would benefit from NKTR-102. We expect topline results from the BEACON study to be available in the first quarter of 2015."